Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2008-02-20

FDA Approved: REYATAZ — Supplemental Application (E.R. Squibb & Sons, L.L.C.)

View source ↗

Summary

The FDA approved a supplemental application for Reyataz (atazanavir) submitted by E.R. Squibb & Sons, L.L.C., resulting in changes to the drug's labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • REYATAZ (atazanavir)

Snippet

SUPPL AP for REYATAZ (ATAZANAVIR)